Clinical trial NCT01252641: Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects
Official title: A Phase 1/2, Open Label, Single Infusion Study of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases (SB-728-T) in HIV Infected Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: HIV
HIV Infection
Keywords: HIV
Lead sponsor: Sangamo Therapeutics
Sponsor class: INDUSTRY
First posted: 2010-12-03
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This research study is being carried out to study a new way to possibly treat human immunodeficiency virus (HIV). The agent is called SB-728-T which are CD4+ T-cells obtained from an individual that are genetically modified at the CCR5 gene by Zinc Finger Nucleases. The CCR5 gene is required for certain types of HIV to enter into and infect T-cells. T cells are one of the white blood cells used by the body to fight HIV. The most important of these are called "CD4+ T-cells"

Some people are born without the CCR5 gene on their T-Cells. These people remain healthy and are resistant to infection with HIV. Other people have a low number of CCR5 genes on their T-cells and their HIV disease is less severe and is slower to cause disease (AIDS).

The purpose of this research study is to find out whether SB-728-T is safe to give to humans and find out how this affects HIV.

Detailed description: Laboratory studies have shown that when CD4+ T-cells are modified with Zinc Finger Nucleases SB-728, HIV is prevented from killing the CD4+ T-cells. On the basis of these laboratory results, there is the potential that this may work in humans infected with HIV and improve their immune system by allowing their CD4+ T-cells to survive longer.

The new treatment to be studied will involve removing white blood cells from the blood that contain CD4+ T-cells. The extracted CD4+ T-cells are then genetically modified by the Zinc finger Nucleases to be resistant to infection by removing the CCR5 gene from the surface of the CD4+ T-cell where HIV enters the cell. Additional genetically modified cells are manufactured and then re-infused back into the individual. Researchers hope that these genetically modified cells will be resistant to infection by HIV and will be able to reproduce additional resistant CD4+ T-cells in your body.

Eligibility criteria: Inclusion Criteria:

* Documented HIV infection
* CD4+ T-cell count \>500 cell per millimeter cubed (cells/mm3)
* CD4+ T-cell nadir of \>400 cells/mm3
* HIV viral load \>1,000 copies per milliliter (mL)

Exclusion Criteria:

* Any viral hepatitis
* Acute HIV infection
* HIV viral load \>1,000,000 copies/mL
* Active or recent (prior 6 months) AIDS defining complication
* Any HIV medications within the past 12 weeks
* Cancer or malignancy that has not been in remission for at least 5 years with the exception of successfully treated basal cell carcinoma of the skin
* Current diagnosis of NYHA grade 3 or 4 congestive heart failure or uncontrolled angina or arrhythmias
* History of bleeding problems
* Use of chronic steroids in past 30 days
* Pregnant or breast feeding
* Active drug or alcohol abuse
* Serious illness in past 30 days
* Currently participating in another clinical trail or any prior gene therapy

Primary outcomes:
measure: Evaluate the safety and tolerability of SB-728-T cells infusion in HIV-1 positive subjects
timeFrame: 12 months
Secondary outcomes:
measure: Evaluate persistence of HIV as measured by HIV-1 RNA,
timeFrame: 12 months
measure: Change in CD4+ T-cell count
timeFrame: 12 months
measure: Persistence of SB-728-T in the peripheral blood
timeFrame: 12 months
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: UCLA CARE Center
state: California
city: Newport Beach
country: United States
facility: Orange Coast Medical Group
state: California
city: San Francisco
country: United States
facility: Quest Clinical Research
state: California
city: Orlando
country: United States
facility: Orlando Immunology Center
state: Florida
Study officials:
affiliation: Sangamo BioSciences, Inc.
name: Winson Tang, M.D.
role: STUDY_DIRECTOR
References: